Twice-Yearly PrEP Shows Promise, Could Boost Adherence

  • Oct 10, 2024

    Recently publicized data from a late-stage clinical trial for an HIV pre-exposure prophylaxis (PrEP) therapy showed promise for twice-yearly treatments, potentially boosting compliance, according to industry experts. Although the Affordable Care Act mandated that all nongrandfathered group and individual health plans must offer no-cost PrEP coverage, compliance continues to be a problem, research reveals.

    When the FDA approved the first injectable treatment for PrEP, the agency hailed the therapy as “an important tool in the effort to end the HIV epidemic” due to its every-two-months regimen, lessening the burden of oral treatments that were taken every day.

    Read more
    © 2024 MMIT
  • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

The Latest
Meet Our Reporters

Meet Our Reporters

×
×